ERBB2 and neoplasm: Analysis revealed that the level of tumor marker HER-2 in the serum was significantly higher in the malignant CMT group than in the benign group and the healthy control group (p < 0.05), while the expression level in the benign CMT group was not significantly different from that of the healthy control group (p > 0.05) (Table 5 and Figure 4).